Moderna shares boosted by estimate-topping financials
Shares in US mRNA specialist Moderna (Nasdaq: MRNA) were 7% higher during Thursday morning’s trading.
The Boston-based company earlier announced its financial results for the first quarter of 2024 and its latest estimates for the year ahead.
"This is the start of a banner year for our vaccine platform"Total revenue for the quarter was $167 million, compared to $1.9 billion in the same period in 2023. The decline was primarily due to reduced sales of the company's Spikevax COVID-19 vaccine. Indeed, revenue from the shot dropped roughly 90% from the same period a year ago. Of the $167 million in Spikevax sales, $100 million came in the USA and $67 million were elsewhere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze